- Jun 11, 2018 -
Company new product attending iron-deficiency anemia protein succinic acid iron oral solution (very high incidence of pregnant women and children), due to have low iron absorption rate is high, the gastrointestinal side effects, etc, effect of iron drugs also has more advantages than others. According to m Intranet disclosure, the domestic treatment of anemia drugs market capacity in 10 billion yuan of above, iron preparations in 4 billion yuan, clinically is given priority to with bivalent iron, iron preparations such as ferrous sulfate, ferrous fumarate tablets, ferrous lactate, polysaccharide iron compound, such as ferrous iron poor taste, patients will have the side effects of nausea and vomiting, especially not suitable for children, succinic acid and protein iron is ferric iron compounds, acidic environment produce sediment in the stomach, don't release iron ions, the intestine higher ph value, the renewed soluble compounds, pancreatic enzyme to make it release of iron to absorb, therefore, the effect of an edge, High iron ion absorption rate, small gastrointestinal side effects), the taste of taking better than iron divalent, the future replacement of iron divalent preparation is the trend.
Protein succinic acid iron is the original Italian ItalfarmacoS. A., went public in 1987, trade name and split has listed more than 20 countries around the world, under its generalization ability is weak, the root of rice Intranet data show that domestic sales also has more than 400 million yuan, the company's protein succinic acid iron is A imitation, 2014-2016, 29.8% compound growth rate of protein succinic acid iron the whole market in China. According to the financial results, the company's sales revenue of protein succinate iron in the first year of its listing in 2016 is expected to exceed 50 million yuan, and the sales revenue in 2017 is expected to be around 180 million yuan, an increase of 260 percent compared with the previous year.